NVIDIA's BioNeMo platform has secured partnerships with Eli Lilly and Thermo Fisher Scientific to accelerate AI-driven drug discovery infrastructure.1 The collaborations extend to biotech innovators including Terray, Apheris, and TetraScience, focusing on foundation model development for pharmaceutical research.1
The BioNeMo platform orchestrates AI workflows that connect laboratory automation with machine learning models. Pharmaceutical companies are using the system to run iterative experiments where AI predictions guide physical lab work, creating feedback loops that refine molecular predictions.1
Several biotech companies have launched products on the platform. Natera, Basecamp Research's EDEN system, Owkin's OwkinZero, Edison's Kosmos, and Boltz Lab have released tools within the ecosystem.1 These launches indicate companies are moving beyond pilot projects to production deployment.
Eli Lilly's participation signals major pharmaceutical validation for the platform. Thermo Fisher's involvement brings laboratory equipment integration, connecting physical instrumentation to AI modeling systems. This hardware-software bridge enables automated experimental design where models propose tests and lab robots execute them.
Terray specializes in small molecule discovery, Apheris provides federated learning infrastructure for sensitive health data, and TetraScience focuses on lab data harmonization. Their combined capabilities address key bottlenecks: data quality, privacy constraints, and experimental throughput.
The lab-in-the-loop approach differs from pure computational drug discovery. AI models generate hypotheses about molecular properties, lab systems test predictions, and results train updated models. This cycle compresses discovery timelines by eliminating manual handoffs between computational and experimental teams.
NVIDIA positions BioNeMo as infrastructure rather than end-user software. The platform provides pre-trained models for protein structure, molecular properties, and biological sequences. Partners customize these foundations for specific therapeutic areas or screening workflows.
The pharmaceutical industry has historically struggled to operationalize AI research. Academic breakthroughs often fail to integrate with regulated manufacturing and clinical pipelines. BioNeMo's partnerships with established pharma and equipment vendors suggest the platform addresses integration challenges that stalled previous attempts.
Multiple concurrent product launches within months indicate ecosystem momentum. When infrastructure platforms reach critical mass, development accelerates as each new tool increases value for others. The BioNeMo ecosystem appears to have crossed this threshold in early 2026.